DNATRIX, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.dnatrix.com
Clinical Trials
4
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)DNX-2440 for Resectable Colorectal Liver Metastasis
Phase 1
Suspended
- Conditions
- Colorectal CancerSquamous Cell CarcinomaLiver Metastasis Colon CancerMelanomaSarcomaLiver MetastasesGastric CancerPeriampullary CancerRenal Cell CancerGastrointestinal Stromal Tumors
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- DNAtrix, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04714983
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida, United States
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
Phase 2
Completed
- Conditions
- Brain CancerGlioblastomaNeoplasm by Histologic TypeNervous System DiseasesBrain NeoplasmGliosarcomaMalignant Brain TumorNeoplasm, NeuroepithelialGliomaNeuroectodermal Tumors
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- DNAtrix, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT02798406
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
Phase 1
Completed
- Conditions
- Glioblastoma or Gliosarcoma
- Interventions
- Drug: Single intratumoral injection of DNX-2401
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- DNAtrix, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT02197169
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
🇺🇸Baylor University: Charles A. Sammons Cancer Center, Dallas, Texas, United States
DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
Phase 1
Completed
- Conditions
- Central Nervous System DiseasesBrain Cancer
- Interventions
- Procedure: Tumor Removal
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- DNAtrix, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT00805376
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
News
No news found